52661 Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open label extension phase 3 trial
作者
Andrew Blauvelt,Peter Foley,Richard G. Langley,Curdin Conrad,David Rosmarin,Ricardo Romiti,Maggie Haitian Wang,Balint Szilagyi,Bengt Hoepken,Richard B. Warren